With the National Institute for Clinical Excellence (NICE) recommendation that another cancer drug, bowel cancer drug Avastin, is not a cost effective use of NHS resources, a serious question is prompted about the NHS’s long term future as the provider of care and treatment of the public.
So says Mike Izzard of the Association of Medical Insurance Intermediaries, "I am truly shocked by this latest development. If the NHS is not able or willing to offer certain cancer drugs where will that leave patients who could really benefit from these drugs? All the major political parties keep claiming they want the best healthcare service and they want to avoid a two-tier healthcare system with the NHS on one side and the private sector on the other. But bit-by-bit the NHS’s potential effectiveness keeps being eroded away by NICE. If the NHS cannot provide the possible live saving treatment which is now available, then the private sector will have to step in more and more with the result that a two tier system becomes inevitable, whatever the political ideals.”